Table 4.

Characteristics and outcomes of six patients with relapse.

Patient No.	Diagnosis	High-Risk Factor at Diagnosis	Disease Status at HSCT	Starting Time of Decitabine (days)	Cycles of Decitabine	Reason for Discontinuation of Decitabine	Bone Marrow Results at Relapse	Time From HSCT to Relapse (days)	Treatment After Relapse	Overall Survival (days)
16	B-ALL	Ph+ WBC >100×109/L	CR1	63	5	Withdrew consent	Marrow blast 97.6% T315I mutation	276	DLI + chemotherapy	433
2	B-ALL	CD10−	CR1	97	8	Completed study	Extramedullary	551	Chemotherapy; TBI; DLI	725
17	B-ALL	Ph+ Age >35	CR2	110	2	Relapse	Marrow blast 42% T315I mutation	168	Automatic discharge	213
3	B-ALL	No	CR2	84	3	Relapse	Marrow blast 49.6%	205	Automatic discharge	244
30	T-LBL	Leukemic phase; WBC>100×109/L	CR1	93	3	Relapse	Extramedullary	156	Chemotherapy	>205
18	B-ALL	Ph+	CR1	60	5	Relapse	Marrow blast 16.4%	221	Chemotherapy	>427

WBC, white blood cell; CR, complete remission; DLI, donor lymphocyte infusion; HSCT, hematopoietic stem cell transplantation.